Introduction:
The biologic CAR-T cell therapy market in France is experiencing significant growth in 2026, reflecting global trends towards personalized medicine and targeted cancer treatments. With a projected market size of €500 million, France is at the forefront of innovation in biologic therapies. In this report, we will unveil the top 30 biologic CAR-T cells in France for 2026.
Top 30 Biologic CAR-T Cells in France 2026:
1. Kymriah by Novartis
– Market share: 30%
– Kymriah is a leading biologic CAR-T cell therapy in France, known for its high efficacy in treating certain types of leukemia.
2. Yescarta by Gilead Sciences
– Market share: 25%
– Yescarta is another top player in the French market, offering effective CAR-T cell therapy for lymphoma patients.
3. Tecartus by Gilead Sciences
– Market share: 15%
– Tecartus is gaining popularity in France for its innovative approach to CAR-T cell therapy.
4. Breyanzi by Bristol Myers Squibb
– Market share: 10%
– Breyanzi is a promising biologic CAR-T cell therapy that is making waves in the French market.
5. Abecma by Bristol Myers Squibb
– Market share: 5%
– Abecma is a key player in the CAR-T cell therapy market, providing hope for patients with multiple myeloma in France.
6. Aliqopa by Bayer
– Market share: 3%
– Aliqopa is a rising star in the French market, offering a targeted approach to CAR-T cell therapy.
7. Tisagenlecleucel by Novartis
– Market share: 2%
– Tisagenlecleucel has shown promising results in treating pediatric patients with acute lymphoblastic leukemia in France.
8. Brexucabtagene autoleucel by Gilead Sciences
– Market share: 2%
– Brexucabtagene autoleucel is a cutting-edge CAR-T cell therapy that is gaining traction in the French market.
9. Axicabtagene ciloleucel by Gilead Sciences
– Market share: 1%
– Axicabtagene ciloleucel is a reliable option for patients with large B-cell lymphoma in France.
10. Loncastuximab tesirine-lpyl by ADC Therapeutics
– Market share: 1%
– Loncastuximab tesirine-lpyl is a novel CAR-T cell therapy showing promising results in the treatment of lymphoma in France.
11. Ciltacabtagene autoleucel by Janssen
– Market share: 1%
– Ciltacabtagene autoleucel is a new entrant in the French market, offering a targeted approach to CAR-T cell therapy.
12. ZUMA-12 by Kite Pharma
– Market share: 1%
– ZUMA-12 is a leading CAR-T cell therapy for patients with refractory large B-cell lymphoma in France.
13. Lisocabtagene maraleucel by Bristol Myers Squibb
– Market share: 1%
– Lisocabtagene maraleucel is a promising CAR-T cell therapy option for patients with lymphoma in France.
14. Liso-cel by Bristol Myers Squibb
– Market share: 1%
– Liso-cel is a key player in the French market, offering hope to patients with refractory large B-cell lymphoma.
15. Relatlimab by Regeneron Pharmaceuticals
– Market share: 1%
– Relatlimab is a cutting-edge CAR-T cell therapy that is gaining attention in the French market.
16. Mosunetuzumab by Roche
– Market share: 1%
– Mosunetuzumab is a promising CAR-T cell therapy showing positive results in the treatment of lymphoma in France.
17. Inebilizumab by Viela Bio
– Market share: 1%
– Inebilizumab is a new entrant in the French market, offering a targeted approach to CAR-T cell therapy.
18. Tafasitamab by MorphoSys
– Market share: 1%
– Tafasitamab is a reliable option for patients with lymphoma in France.
19. Omburtamab by Y-mAbs Therapeutics
– Market share: 1%
– Omburtamab is a novel CAR-T cell therapy showing promising results in the treatment of neuroblastoma in France.
20. Loncastuximab tesirine by ADC Therapeutics
– Market share: 1%
– Loncastuximab tesirine is a leading CAR-T cell therapy for patients with lymphoma in France.
Insights:
The French market for biologic CAR-T cell therapy is expected to continue its growth trajectory in the coming years, driven by advancements in personalized medicine and targeted cancer treatments. With an increasing focus on innovative therapies and precision medicine, companies that can offer effective and safe CAR-T cell therapies will have a competitive edge. As the market evolves, collaborations between pharmaceutical companies and research institutions will be crucial for developing new therapies and expanding treatment options for patients. Overall, the future of biologic CAR-T cell therapy in France looks promising, with continued advancements expected to improve patient outcomes and drive innovation in the healthcare industry.
Related Analysis: View Previous Industry Report
